Tech Company Financing Transactions
Genascence Funding Round
On 5/10/2022, Genascence raised $10.5 million in Series A funding from Pacira Pharmaceuticals, DeepWork Capital and Polymerase Capital.
Transaction Overview
Company Name
Announced On
5/10/2022
Transaction Type
Venture Equity
Amount
$10,500,000
Round
Series A
Investors
Pacira Pharmaceuticals (Lead Investor)
DeepWork Capital (Jackson Streeter)
Proceeds Purpose
The company intends to use the proceeds to accelerate clinical development of GNSC-001, its lead program in osteoarthritis (OA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3225 Ash Street
Palo Alto, CA 94306
USA
Palo Alto, CA 94306
USA
Phone
Website
Email Address
Overview
We're taking on one of the largest problems in all of medicine -- the leading cause of disability and chronic pain, and a significant risk factor for opioid addiction -- osteoarthritis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Chalberg
Co-Founder
Christopher Evans
Co-Founder
Paul Robbins
Browse more venture capital transactions:
Prev: 5/9/2022: AskGene Pharma venture capital transaction
Next: 5/10/2022: OtterTune venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs